Strides Pharma Science
STAR
Strides Pharma Science Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 1,79,670 |
| Weekly | 6.70% | 13,68,422 |
| Monthly | 8.15% | 32,42,169 |
Strides Pharma Science Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| STAR | - | 6.70% | 8.15% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Strides Pharma Science Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| STAR | 17.27 | 1.12 | 17.32 | -4.38 | -2.55 | - |
| Index | 36.20 | 6.77 | 17.25 | 17.89 | 19.69 | 1.20 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Strides Pharma Science Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -0.43% | -38.04% | -4.38% | -2.55% |
| FY '20-21 | 15.14% | 45.95% | 7.68% | 7.76% |
| FY '19-20 | -0.71% | -25.46% | 4.80% | 5.58% |
Strides Pharma Science Shareholding Pattern
Strides Pharma Science Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 2,524.63 | 2,496.36 | 156 | -91.62 |
| FY '20-21 | 2,586.72 | 2,193.70 | 481.29 | 209.92 |
| FY '19-20 | 2,221.95 | 1,861.77 | 433.27 | 135.43 |
Strides Pharma Science Share Price
Strides Pharma Science Limited is an Indian pharmaceutical company. The company focuses on the development and production of IP-based niche and pharmaceutical products. It operates in two segments: Pharmaceuticals and Biopharmaceuticals. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India and others. The company manufactures a variety of niche and pharmaceutical products, including various dosage forms such as liquids, ointments and creams, soft gels, sachets, tablets and controlled dosage forms. It has eight manufacturing facilities in India (Bengaluru, Puducherry and Chennai), Singapore, Italy (Milan), USA (Florida) and Kenya (Nairobi). It also makes soft gelatin capsules. It develops and manufactures drugs for the antiretroviral, antimalarial, tuberculosis, hepatitis and other infectious disease drug segments for its institutional business.